Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis

[1]  P. Vlachos,et al.  A randomized double-blind trial comparing the efficacy, safety, and immunogenicity of MSB11022, a proposed biosimilar of adalimumab, versus adalimumab originator in patients with moderate-to-severe plaque psoriasis , 2018, Journal of American Academy of Dermatology.

[2]  R. Moots,et al.  Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis , 2018, Current Rheumatology Reports.

[3]  C. Allaart,et al.  Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry , 2018, Annals of the rheumatic diseases.

[4]  R. Schilsky,et al.  Rationale, Opportunities, and Reality of Biosimilar Medications , 2018, The New England journal of medicine.

[5]  T. Hickling,et al.  Immunoassay methods used in clinical studies for the detection of anti‐drug antibodies to adalimumab and infliximab , 2018, Clinical and experimental immunology.

[6]  M. Péntek,et al.  The Economic Impact of Biosimilars on Chronic Immune-Mediated Inflammatory Diseases. , 2018, Current pharmaceutical design.

[7]  J. Kalden,et al.  Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment , 2017, Nature Reviews Rheumatology.

[8]  J. Yfantopoulos,et al.  Assessment of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in psoriasis , 2017, Archives of Dermatological Research.

[9]  R. Moots,et al.  The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study , 2017, PloS one.

[10]  M. Rossi,et al.  Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira® , 2016, mAbs.

[11]  P. Vlachos,et al.  Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira® in healthy subjects , 2016, British journal of clinical pharmacology.

[12]  T. Wyant,et al.  Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance , 2016, Journal of immunology research.

[13]  R. Thorpe,et al.  Immunogenicity assessment of monoclonal antibody products: A simulated case study correlating antibody induction with clinical outcomes. , 2015, Biologicals : journal of the International Association of Biological Standardization.

[14]  M. Nurmohamed,et al.  Key findings towards optimising adalimumab treatment: the concentration-effect curve. , 2015, Annals of the rheumatic diseases.

[15]  V. Devanarayan,et al.  Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical Recommendations , 2014, The AAPS Journal.

[16]  B. Dijkmans,et al.  Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. , 2011, JAMA.

[17]  K. Patra,et al.  Disease Activity, Physical Function, and Radiographic Progression After Longterm Therapy with Adalimumab Plus Methotrexate: 5-Year Results of PREMIER , 2010, The Journal of Rheumatology.

[18]  Frederick Wolfe,et al.  Rheumatoid arthritis , 2010, The Lancet.

[19]  A. Silman,et al.  Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative , 2010 .

[20]  Tsutomu Takeuchi,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update , 2010, Annals of the rheumatic diseases.

[21]  J F Fries,et al.  The Health Assessment Questionnaire (HAQ). , 2005, Clinical and experimental rheumatology.

[22]  E. Keystone,et al.  Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. , 2004, Arthritis and rheumatism.

[23]  G. Firestein.  Evolving concepts of rheumatoid arthritis , 2003, Nature.

[24]  J J Anderson,et al.  American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[25]  C. McHorney,et al.  The MOS 36‐Item Short‐Form Health Survey (SF‐36): II. Psychometric and Clinical Tests of Validity in Measuring Physical and Mental Health Constructs , 1993, Medical care.

[26]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[27]  F. Arnett.  Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[28]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[29]  F. Breedveld,et al.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. , 2006, Arthritis and rheumatism.

[30]  Ware J.E.Jr.,et al.  THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION , 1992 .